French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program.
Prostacyclins reduced pulmonary vascular resistance while significantly increasing cardiac index and right ventricular power — the heart working harder to push more blood through. Sotatercept also reduced pulmonary vascular resistance, but without increasing cardiac index, and actually decreased right ventricular power.
The authors suggest these contrasting effects may reflect fundamentally different mechanisms of action, or differences in patient characteristics at baseline.
Citation
Genecand L, Boucly A, Beurnier A, Jaïs X, Degano B, Prevot G, Gerges C, Lamblin N, Bauer F, Savale L, Sitbon O, Chemla D, Humbert M, Montani D. Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients. J Heart Lung Transplant. 2026 Jun 1:S1053-2498(26)01936-4. doi: 10.1016/j.healun.2026.05.028. Epub ahead of print. PMID: 42229625.
Read more at this link in the Journal of Heart and Lung Transplantation